It is really good to have the video here. Yesterday's conf. call was also very informative, particularly the Q&A session on VX-222. I hope this along with TVR, 770, 809, and 509 are those four or five products that Emmens promised to be visible a year from now. I have been listening to the Q&A over and over again. Emmens made some bold statements in the interview with Mike Huckman, but if you have followed the history of Gilead's drugs, you cannot find a sigle product that was organically generated as TVR is.
Very few "small" biotech companies have an executive team with the experience in the pharmaceutical industry and successful records that Messers Emmens and Graves bring to Vertex. With 1,400 employess worldwide, ready to take multiple drugs in its pipline through the approval process and to market in the nest two years, Vertex has an infrastructure in place that it is on the verge of making Mr. Emmens goal a reality. The current market cap of Vertex affirms the street's opinion that the company has the potential to be the next big independent bio-pahrma company success story. The next 12 to 24 months of cinical data will certainly be the "rocket fuel" that propels this company into the likes of the large biotechs Mr. Emmens referred to, and shorts had better be wary that he has the track record and the company's pipeline of drug candidates has the market potential to pull it off.
I'm not sure you can accurately classify Vertex as a "small biotech". And if you understand the Hep C market, it's not all that small either and obviously even Schering is concerned about Telaprevir's progress, so I'm not sure it is a stretch make the comparision.
I did notice he didn't want to answer the $40,000 dollar question, most likely because the answer is a bit closer to $70,000. Just take a guess what Schering gets for SOC these days...the numbers aren't that crazy in comparision. Although the whole thing is a bit crazy...so many of us needing the treatment asap.
So tired, tired of waiting, tired of waiting for you....